We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App




World's First Sensor-Enabled Ablation Catheter Designed to Treat Atrial Fibrillation

By HospiMedica International staff writers
Posted on 22 May 2023

Atrial fibrillation (AFib), the most common irregular heart rhythm condition, impacts over 37 million people worldwide, a figure projected to more than double by 2050. More...

With an additional five million cases diagnosed annually, this escalating health concern creates the need for innovative solutions for patients as well as their healthcare providers. Now, a first-of-its-kind ablation catheter designed with a unique flexible electrode tip and contact force sensing, promises shorter procedure times and improved safety for AFib treatment.

Abbott’s (Abbott Park, IL, USA) TactiFlex Ablation Catheter, Sensor Enabled, is the world's first ablation catheter with a flexible tip and contact force technology. The TactiFlex catheter is designed for use with Abbott's EnSite X EP heart mapping system, allowing physicians to view and precisely pinpoint the heart areas requiring ablation. The use of the TactiFlex catheter with the EnSite X EP System enhances visualization for physicians, thereby allowing for higher accuracy and precision, leading to safer and shorter procedures.

In contrast to other catheters available in the market, the TactiFlex catheter utilizes a laser-cut pattern tip design that flexes upon contact with the heart wall. This aids in directing fluid to the treated tissue and ensures more precise catheter positioning – providing stability that's up to twice as high in a beating heart – for consistent therapy delivery. The Abbott TactiFlex catheter demonstrated robust clinical outcomes in the TactiFlex AF IDE study, creating rapid, safe lesions to treat AFib with an acute procedural success rate surpassing 99%. The TactiFlex catheter has been granted approval for usage in Europe, Japan, Africa, and Australia, and has now also received clearance from the U.S. Food and Drug Administration (FDA).

"Abbott is leading the way in helping doctors manage common arrhythmias with the most holistic portfolio for this condition in the world," said Christopher Piorkowski, M.D., chief medical officer of Abbott's electrophysiology business. "The EnSite X EP System is unmatched in determining the exact location where ablation is required. Coupled with the TactiFlex catheter, patients can now feel even more confident that their procedure will deliver safe and effective results."

Related Links:
Abbott 


Gold Member
12-Channel ECG
CM1200B
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Short Phlebotomy Cart
MSWA-3469-WHT
New
MR Trolley
MR9002
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: New clinical guidance suggests treatments to prevent blood clots in CLTI patients after leg artery procedures (Photo courtesy of Shutterstock)

Stronger Blood Clot Prevention Measures Needed After Leg Artery Procedures in High-Risk Patients

Chronic limb-threatening ischemia (CLTI), the most severe form of peripheral artery disease (PAD), significantly reduces blood flow to the legs and feet. Despite undergoing lower limb revascularization... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: A research collaboration aims to further advance findings in human genomics research in cardiovascular diseases (Photo courtesy of 123RF)

Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies

A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.